Suppr超能文献

一项回顾性观察研究比较了联合使用长效β激动剂和皮质类固醇与分别使用长效β激动剂和皮质类固醇的儿童中急救药物的使用情况。

A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids.

机构信息

Department of Child Health, Division of Applied Health Sciences, School of Medicine, University of Aberdeen, Aberdeen, UK.

出版信息

Arch Dis Child. 2010 Oct;95(10):817-21. doi: 10.1136/adc.2009.179069. Epub 2010 Jul 23.

Abstract

BACKGROUND

Data on the efficacy and safety of long-acting β2-agonists (LABA) in children are limited, and current guidelines recommend that LABA always be used with inhaled corticosteroids (ICS).

OBJECTIVE

To compare asthma control, assessed by rescue medications use, in children prescribed LABA and ICS as a fixed-dose combination (LABA/ICS) or concurrently via separate inhalers (LABA+ICS).

METHODS

Retrospective observational study of asthma medication prescribed to children aged 0-18 years registered with 40 primary care practices for the years 2002-6. Asthma control, reflected by requirement for oral corticosteroids (OCS) and/or six or more short-acting β2-agonist (SABA) canisters per year, was assessed for children prescribed LABA/ICS or LABA+ICS.

RESULTS

10,454 (8%) of all registered children received at least one prescription for asthma medication over the study period. Prescribing of LABA/ICS increased significantly, with a concomitant decrease in prescribing of LABA+ICS. Use of OCS increased by 60%, with the lowest use in children prescribed only SABA and highest use in those prescribed LABA. Children prescribed LABA/ICS were significantly less likely than those prescribed LABA+ICS to require OCS rescue therapy and or >6 SABA inhalers a year (OR 1.6; 95% CI 1.1 to 2.2; p=0.04 and OR 1.7; 95% CI 1.1 to 2.5; p=0.005, respectively, for the years 2005-6).

CONCLUSIONS

The results of this retrospective observational study suggest that children prescribed fixed-dose LABA-and-ICS combination devices achieve better asthma control, as reflected in reduced requirements for SABA and reduced courses of OCS than equivalent doses in separate devices.

摘要

背景

有关长效β2-激动剂(LABA)在儿童中的疗效和安全性的数据有限,目前的指南建议 LABA 始终与吸入皮质类固醇(ICS)联合使用。

目的

比较同时使用固定剂量联合制剂(LABA/ICS)或通过单独吸入器(LABA+ICS)给药的儿童,使用 LABA 和 ICS 的哮喘控制情况,评估方法为使用急救药物。

方法

回顾性观察研究了 2002 年至 2006 年在 40 个基层医疗机构登记的 0-18 岁儿童开具的哮喘药物。通过每年口服皮质类固醇(OCS)和/或 6 个或更多短效β2-激动剂(SABA)罐的需求来评估儿童接受 LABA/ICS 或 LABA+ICS 的哮喘控制情况。

结果

在研究期间,所有登记儿童中有 10454 名(8%)至少接受了一次哮喘药物处方。LABA/ICS 的处方明显增加,同时 LABA+ICS 的处方减少。OCS 的使用增加了 60%,在仅接受 SABA 治疗的儿童中使用量最低,在接受 LABA 治疗的儿童中使用量最高。与接受 LABA+ICS 治疗的儿童相比,接受 LABA/ICS 治疗的儿童接受 OCS 急救治疗和/或每年需要 >6 个 SABA 吸入器的可能性明显降低(OR 1.6;95%CI 1.1 至 2.2;p=0.04 和 OR 1.7;95%CI 1.1 至 2.5;p=0.005,分别为 2005 年至 2006 年)。

结论

这项回顾性观察研究的结果表明,与使用单独设备时等效剂量相比,使用固定剂量 LABA 和 ICS 联合装置的儿童哮喘控制更好,反映为对 SABA 的需求减少和 OCS 疗程减少。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验